Biopharmaceuticals China

This content was created by Boehringer Ingelheim BioXcellence™

Boehringer Ingelheim entered the Chinese market in 1994, establishing its headquarters in Shanghai and expanding operations nationwide. Today, the company employs approximately 3,700 people across China, focusing on Human Pharma, Animal Health, and Biopharmaceutical Contract Development and Manufacturing. With a comprehensive value chain that includes R&D, manufacturing, commercial operations, and external innovation partnerships, Boehringer Ingelheim has embedded China’s unique needs into its global R&D strategy. The company is committed to delivering innovative products to patients in China faster, advancing the nation’s healthcare industry, and improving the health and well-being of both humans and animals.

Sustainability has been a cornerstone of Boehringer Ingelheim’s mission since its founding. In 2021, the company launched its “Sustainable Development for Generations (SD4G)” strategy, which focuses on three pillars: More Health, More Potential, and More Green. In China, Boehringer Ingelheim has introduced several sustainable development initiatives that align with the country’s social priorities and future business challenges. These efforts aim to foster sustainable business growth while contributing to China’s economic and social progress.

Recognized for its commitment to employees and workplace excellence, Boehringer Ingelheim has been certified as a “Top Employer” in China for 11 consecutive years since 2014.